These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 31545293)

  • 1. Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
    Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Biomed Pharmacother; 2019 Oct; 118():109356. PubMed ID: 31545293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
    Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft.
    Natarajan A; Ramachandran B; Gopisetty G; Jayavelu S; Sundersingh S; Rajkumar T
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):361-371. PubMed ID: 33015747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma.
    Igarashi K; Kawaguchi K; Li S; Han Q; Tan Y; Murakami T; Kiyuna T; Miyake K; Miyake M; Singh AS; Eckardt MA; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Singh SR; Eilber FC; Hoffman RM
    Cancer Lett; 2018 Mar; 417():168-173. PubMed ID: 29306021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma.
    Xia YZ; Yang L; Xue GM; Zhang C; Guo C; Yang YW; Li SS; Zhang LY; Guo QL; Kong LY
    Oncotarget; 2016 Aug; 7(35):56371-56382. PubMed ID: 27486760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model.
    Zhou ZY; Wan LL; Yang QJ; Han YL; Li D; Lu J; Guo C
    Toxicol Lett; 2016 Sep; 259():124-132. PubMed ID: 27491883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment.
    Mashayekhi S; Yousefi B; Tohidi E; Darband SG; Mirza-Aghazadeh-Attari M; Sadighparvar S; Kaviani M; Shafiei-Irannejad V; Kafil HS; Karimian A; Jadidi-Niaragh F; Majidinia M
    J Cell Biochem; 2019 Sep; 120(9):15719-15729. PubMed ID: 31087712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
    Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
    Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
    Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
    Anticancer Res; 2021 Jul; 41(7):3287-3292. PubMed ID: 34230123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription.
    Cheng M; Cai W; Huang W; Chen Y; Wu Z; Luo P; Yan W
    Eur J Pharmacol; 2018 Dec; 840():1-8. PubMed ID: 30273544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line.
    Rajkumar T; Yamuna M
    Anticancer Drugs; 2008 Mar; 19(3):257-65. PubMed ID: 18510171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model.
    Wu NF; Yamamoto J; Aoki Y; Masaki N; Samonte C; Wu J; Bouvet M; Hoffman RM
    Anticancer Res; 2021 Oct; 41(10):4715-4718. PubMed ID: 34593419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model.
    Higuchi T; Sugisawa N; Yamamoto J; Oshiro H; Han Q; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Tan Y; Kuchipudi S; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):285-291. PubMed ID: 31705268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
    Kiyuna T; Tome Y; Miyake K; Murakami T; Oshiro H; Igarashi K; Kawaguchi K; Hsu J; Singh M; Li Y; Nelson S; Bouvet M; Singh SR; Kanaya F; Hoffman RM
    Anticancer Res; 2019 Sep; 39(9):4775-4779. PubMed ID: 31519578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequentially degradable hydrogel-microsphere loaded with doxorubicin and pioglitazone synergistically inhibits cancer stemness of osteosarcoma.
    Cao J; Du X; Zhao H; Zhu C; Li C; Zhang X; Wei L; Ke X
    Biomed Pharmacother; 2023 Sep; 165():115096. PubMed ID: 37421781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiapoptotic and anti-inflammatory effects of Pparγ agonist, pioglitazone, reversed Dox-induced cardiotoxicity through mediating of miR-130a downregulation in C57BL/6 mice.
    Pakravan G; Peymani M; Abedpoor N; Safaeinejad Z; Yadegari M; Derakhshan M; Nasr Esfahani MH; Ghaedi K
    J Biochem Mol Toxicol; 2022 Jun; 36(6):e23041. PubMed ID: 35343021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of P-glycoprotein-mediated multidrug resistance in SGC7901/VCR cells by PPARgamma activation by troglitazone.
    Chen Q; Zhou J; Jiang C; Chen J
    J Huazhong Univ Sci Technolog Med Sci; 2010 Jun; 30(3):326-31. PubMed ID: 20556576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPARγ-dependent anti-tumor and immunomodulatory actions of pioglitazone.
    El-Sisi AE; Sokar SS; Salem TA; Abu Risha SE
    J Immunotoxicol; 2015; 12(4):308-16. PubMed ID: 25425470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines.
    Levi M; Salaroli R; Parenti F; De Maria R; Zannoni A; Bernardini C; Gola C; Brocco A; Marangio A; Benazzi C; Muscatello LV; Brunetti B; Forni M; Sarli G
    BMC Vet Res; 2021 Jan; 17(1):30. PubMed ID: 33461558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.